期刊文献+

不同浓度β-淀粉样蛋白寡聚体的毒性差异 被引量:3

Different neurotoxicities of different concentrations of oligomeric amyloid beta
原文传递
导出
摘要 目的探讨不同浓度的β淀粉样蛋白(amyloid beta,Aβ)寡聚体毒性的差异。方法 0.5μmol/L,1μmol/L,1.5μmol/L,2μmol/L,2.5μmol/L,3μmol/L的Aβ1-42寡聚体(A-βderived diffusible ligands,ADDLs)处理PC12细胞(大鼠肾上腺嗜铬细胞瘤细胞),western blot检测钙蛋白酶(calpain)的激活程度,蛋白激酶A的催化亚基(catalytic subunits of cAMP-dependent kinase,PKA-C)和磷酸化环磷酸腺苷反应元件结合蛋白(phosphory lated cAMP response element binding protein,pCREB)的表达水平。结果所有浓度的ADDLs均导致pCREB的下降(P<0.05),但均未影响PKA-C的含量(P>0.05)。0.5μmol/L,1μmol/L,1.5μmol/L的ADDLs导致pCREB的下降与calpain的激活无关,而2μmol/L,2.5μmol/L,3μmol/L的ADDLs导致pCREB的下降与calpain激活有关。结论不同浓度ADDLs通过不同毒性通路导致pCREB下降:高浓度的ADDLs通过激活calpain,而低浓度ADDLs则可能通过其他途径,但两者均未通过影响PKA-C的含量来降低pCREB水平。 Objective To investigate the different neurotoxities of different concentrations of oligomeric amyloid beta.Methods PC12 cells were treated with 0.5 μmol/L,1 μmol/L,1.5 μmol/L,2 μmol/L,2.5 μmol/L and 3 μmol/L Aβ1-42 oligomers(Aβ-derived diffusible ligands,ADDLs).The activation of calpain and protein level of catalytic subunits of PKA(PKA-C) and phosphorylated cAMP response element binding protein(pCREB) were analysed by western blot.Results All concentrations of ADDLs could decrease pCREB(P0.05),but had no impact on PKA-C levels(P0.05).While 2 μmol/L,2.5 μmol/L and 3 μmol/L ADDLs decreased pCREB through activation of calpain,0.5 μmol/L,1 μmol/L and 1.5 μmol/L ADDLs decreased pCREB through other mechanisms.Conclusions Different concentrations of ADDLs decreased pCREB though different ways: high concentrations through activation of calpain,while low concentrations through other mechanisms.However,neither decreased pCREB levels through impact on the levels of PKA-C.
出处 《卒中与神经疾病》 2010年第6期323-325,329,共4页 Stroke and Nervous Diseases
关键词 阿尔茨海默病 β-淀粉样蛋白寡聚体 钙蛋白酶 蛋白激酶A 磷酸化环磷酸腺苷反应元件结合蛋白 Alzheimer's disease Aβ-derived diffusible ligands Calpain cAMP-dependent kinase Phosphorylated cAMP response element binding protein
  • 相关文献

参考文献10

  • 1Haass C,Selkoe DJ.Soluble protein oligomers in neurodegeneration:lessons from the Alzheimer's amyloid beta-peptide.Nature Reviews in Molecular Cell Biology.2007,8(2):101-112.
  • 2Olivier Thibault,John C.Gant and Philip W.Landfield.Expansion of the calcium hypothesis of brain aging and Alzheimer's disease:minding the store.Aging Cell,2007,6(3):307-317.
  • 3Peter J,Susan-Marie EH,Anthony RW,et al.Mechanisms of Aβ mediated neurodegeneration in Alzheimer's disease.The International Journal of Biochemistry& Cell Biology,2008,40(2):181-198.
  • 4Blaine Stine W,Karie ND,Grant AK,et al.In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis.The Journal of Biological Chemistry,2003,278(13):11612-11622.
  • 5Kelly BL,Ferreira A.β-amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons.J Biol Chem,2006,281(38):28079-28089.
  • 6Han-qing Xie and Gail VW.Johnson.Ceramide selectively decreases tau levels in differentiated PC12 cells through modulation of calpain I.Journal of neurochemistry,1997,69(3):1020-1030.
  • 7Tali Vaisid,Nechama SK,Esther Elkind,et al.Amyloid β peptide toxicity in differentiated PC12 cells:calpain-calpastatin,caspase,and membrane damage.Journal of Neuroscience Research,2008,86(10):2314-2325.
  • 8Vitolo OV,Sant Angelo A,Costanzo V,et al.Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation:reversibility by drugs that enhance cAMP signaling.Proc Natl Acad Sci USA,2002,99(20):13217-13221.
  • 9Lindsay CR,Wenru Zhang,Giulio Taglialatela,et al.Selective induction of calcineurin activity and signaling by oligomeric amyloid beta.Aging cell,2008,7(6):824-835.
  • 10Matsushita M,Tomizawa K,Moriwaki A,et al.A high-efficiency protein transduction system demonstrating the role of PKA in long-lasting long-term potentiation.J Neurosci,2007,21(16):6000-6007.

同被引文献31

  • 1Gregory J L, Prada C M, Fine S J, et al. Reducing avai- lable soluble β-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice [ J ]. Neuropathol Exp Neurol,2012,71 ( 11 ) : 1009-1017.
  • 2Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer' s disease : an appraisal for the development of therapeutics [ J ]. Nat Rev Drug Discov,2011,10(9) :698-712.
  • 3Breyhan H,Wirths 0, Duan K, et al. APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy [J ]. Acta Neuropatho1,2009, 117 (6) :677-685.
  • 4Dubois B, Feldman H H, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer' s disease: the IWG-2 criteria [ J ]. Lancet Neurol, 2014, 13 ( 8 ) : 614-629.
  • 5Rosenberg R N. The molecular and genetic basis of AD:the end of the beginning: the 2000 Wartenberg lecture [ J]. Neurology,2000,54( 11 ) :2045-2054.
  • 6Sambamurti K,Greig N H, Lahiri D K. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer' s disease [ J ]. Neuromolecular Med ,2002,1 ( 1 ) : 1-31.
  • 7Tanzi R E,Bertram L. Twenty years of the Alzheimer' s disease amyloid hypothesis : a genetic perspective [ J ]. Cell, 2005,20 ( 4 ) : 545-555.
  • 8Sagare A P, Deane R, Zlokovic B V. Lowdensity lipop- rotein receptor-related protein l:a physiological Aβ homeostatic mechanism with multiple therapeutic oppor- tunities. [ J ]. Pharmthera,2012,136( 1 ) :94-105.
  • 9Paxinos G, Franklin KBJ. The mouse brain in stereotaxic coordinates [ M ]. 2nd edition. London: Academic Pre- ss,2001.
  • 10Hefti F, Goure W F, Jerecic J, et al. The case for soluble Aβ oligomers as a drug target in Alzheimer' s disease[J]. Trends in Pharmacol Sci,2013,34(5):261-266.

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部